ZyVersa Therapeutics Reports First Quarter 2025 Financial Results and Highlights Pipeline Progress
Provided By GlobeNewswire
Last update: May 12, 2025
KEY HIGHLIGHTS
WESTON, Fla., May 12, 2025 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical-stage specialty biopharmaceutical company developing first-in-class drugs for the treatment of renal and inflammatory diseases with high unmet medical needs, reports financial results for the quarter ended March 31, 2025, and provides pipeline update.
Read more at globenewswire.com
